New Light Shed on Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Inhibitors in Parkinson's Disease.

João PL Daher, Hisham A Abdelmotilib, Xianzhen Hu, Laura A Volpicelli-Daley, Mark S Moehle, Kyle B Fraser, Elie Needle, Yi Chen, Stefanus J Steyn, Paul Galatsis, Warren D Hirst, Andrew B West, None, Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration Journal of Biological Chemistry. ,vol. 290, pp. 19433- 19444 ,(2015) , 10.1074/JBC.M115.660001

Doriano Fabbro, 25 years of small molecular weight kinase inhibitors: potentials and limitations. Molecular Pharmacology. ,vol. 87, pp. 766- 775 ,(2015) , 10.1124/MOL.114.095489

Jaclyn L. Henderson, Bethany L. Kormos, Matthew M. Hayward, Karen J. Coffman, Jayasankar Jasti, Ravi G. Kurumbail, Travis T. Wager, Patrick R. Verhoest, G. Stephen Noell, Yi Chen, Elie Needle, Zdenek Berger, Stefanus J. Steyn, Christopher Houle, Warren D. Hirst, Paul Galatsis, Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. Journal of Medicinal Chemistry. ,vol. 58, pp. 419- 432 ,(2015) , 10.1021/JM5014055

Mark R. Cookson, The role of leucine-rich repeat kinase 2 ( LRRK2 ) in Parkinson's disease Nature Reviews Neuroscience. ,vol. 11, pp. 791- 797 ,(2010) , 10.1038/NRN2935